JP2008528468A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528468A5
JP2008528468A5 JP2007551743A JP2007551743A JP2008528468A5 JP 2008528468 A5 JP2008528468 A5 JP 2008528468A5 JP 2007551743 A JP2007551743 A JP 2007551743A JP 2007551743 A JP2007551743 A JP 2007551743A JP 2008528468 A5 JP2008528468 A5 JP 2008528468A5
Authority
JP
Japan
Prior art keywords
compound
formula
optionally
hydrogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007551743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528468A (ja
JP5475234B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2006/000204 external-priority patent/WO2006077424A1/en
Publication of JP2008528468A publication Critical patent/JP2008528468A/ja
Publication of JP2008528468A5 publication Critical patent/JP2008528468A5/ja
Application granted granted Critical
Publication of JP5475234B2 publication Critical patent/JP5475234B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007551743A 2005-01-21 2006-01-20 医薬化合物 Expired - Fee Related JP5475234B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US64598705P 2005-01-21 2005-01-21
US64597605P 2005-01-21 2005-01-21
US64598605P 2005-01-21 2005-01-21
US64597505P 2005-01-21 2005-01-21
US64611305P 2005-01-21 2005-01-21
US60/645,976 2005-01-21
US60/645,975 2005-01-21
US60/646,113 2005-01-21
US60/645,987 2005-01-21
US60/645,986 2005-01-21
PCT/GB2006/000204 WO2006077424A1 (en) 2005-01-21 2006-01-20 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
JP2008528468A JP2008528468A (ja) 2008-07-31
JP2008528468A5 true JP2008528468A5 (enExample) 2009-03-19
JP5475234B2 JP5475234B2 (ja) 2014-04-16

Family

ID=35911102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007551743A Expired - Fee Related JP5475234B2 (ja) 2005-01-21 2006-01-20 医薬化合物

Country Status (10)

Country Link
US (1) US20080161251A1 (enExample)
EP (1) EP1845974A1 (enExample)
JP (1) JP5475234B2 (enExample)
KR (1) KR101345002B1 (enExample)
CN (1) CN101146532B (enExample)
AU (1) AU2006207321B2 (enExample)
BR (1) BRPI0606480A (enExample)
CA (1) CA2594474C (enExample)
MX (1) MX2007008810A (enExample)
WO (1) WO2006077424A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
WO2006077425A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CN101133088B (zh) * 2005-03-03 2011-04-13 三菱丽阳株式会社 聚合物粒子、含有它的树脂组合物、成型体
ES2374428T3 (es) * 2005-08-02 2012-02-16 Trustees Of Tufts College Métodos para la deposición progresiva de recubrimientos de fibroína de seda.
CA2651152A1 (en) * 2006-05-05 2007-11-15 Astex Therapeutics Limited 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
WO2008007123A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical compounds
EP2049106A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
JP2011528798A (ja) * 2008-07-23 2011-11-24 エフ.ホフマン−ラ ロシュ アーゲー 抗血管形成療法のモニター
AU2009324464B2 (en) * 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2010104306A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
TR201904614T4 (en) 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
KR20180008594A (ko) 2015-05-18 2018-01-24 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 및 그의 용도
EP3297440A4 (en) 2015-06-19 2019-04-10 Syn-Nat Products Enterprise LLC COMPOSITION WITH CARBOPLATIN AND USE
JP6768716B2 (ja) * 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
KR20180021805A (ko) 2015-06-25 2018-03-05 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 조성물 및 이의 용도
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
BR112019003722A2 (pt) 2016-08-23 2019-05-28 Eisai R&D Man Co Ltd terapias de combinação para o tratamento de carcinoma hepatocelular
KR102515694B1 (ko) 2017-01-10 2023-03-29 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物(二)
WO2018170447A1 (en) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
CN107235906B (zh) * 2017-06-28 2020-05-01 郑州大学第一附属医院 一组吡唑酰胺类衍生物及其应用
CN107686477B (zh) * 2017-09-30 2020-01-31 武汉九州钰民医药科技有限公司 作为cdk4/6抑制剂的新型化合物及其应用
CN110776501B (zh) * 2019-08-22 2021-04-02 联宁(苏州)生物制药有限公司 一种用于抗体药物偶联物的药物毒素pnu-159682的制备方法及其中间体
TWI759829B (zh) 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
IL272145A (en) 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic compositions with protein concentrate from conditioned medium of adipose-derived stem cells
KR102549327B1 (ko) * 2021-01-20 2023-06-29 연세대학교 산학협력단 저분화 화합물의 조합을 유효성분으로 포함하는 뇌종양의 예방 또는 치료용 조성물
CN116041324B (zh) * 2022-11-20 2025-05-23 药康众拓(北京)医药科技有限公司 一种氘代吡唑二氯苯甲酰胺类化合物、药物组合物和用途
CN120081825B (zh) * 2025-05-07 2025-09-16 天津匠新致成科技有限公司 一种化合物及其制备方法和医药用途
CN120081789B (zh) * 2025-05-07 2025-08-29 天津匠新致成科技有限公司 具有抗肿瘤活性的吡唑衍生物及其制备方法和应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2512572A (en) 1950-06-20 Substituted pteridines and method
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US3803124A (en) 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
DE2124023C3 (de) 1970-05-27 1980-07-10 Richter Gedeon Vegyeszeti Gyar R.T., Budapest Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin oder von deren Sulfaten
CH605550A5 (enExample) 1972-06-08 1978-09-29 Research Corp
AR204004A1 (es) 1973-04-02 1975-11-12 Lilly Co Eli Procedimientos para preparar derivados de vinblastina leurosidina y leurocristina
GB1457632A (en) 1974-03-22 1976-12-08 Farmaceutici Italia Adriamycins
US4020270A (en) 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
GB1467383A (en) 1974-06-12 1977-03-16 Farmaceutici Italia Daunomycin analogues
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
US4197249A (en) 1977-08-15 1980-04-08 American Cyanamid Company 1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
EP0111058B1 (en) 1982-11-26 1987-11-04 Nippon Kayaku Kabushiki Kaisha Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4691918A (en) 1985-10-08 1987-09-08 Diversified Products Corporation Multiple exercise device
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
IL96531A (en) 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
JPH05507480A (ja) * 1990-05-26 1993-10-28 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 医薬品抵抗性の克服の際に使用するための1,4―ジヒドロピリジン
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
IT1250692B (it) 1991-07-23 1995-04-21 Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi.
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
DE4222910A1 (de) 1992-07-11 1994-01-13 Asta Medica Ag Neue Phospholipidderivate
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
WO1997027852A1 (en) * 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
DE69728986T2 (de) 1996-06-21 2005-04-07 Allergan, Inc., Irvine Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CN1158269C (zh) 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6166244A (en) 1999-05-07 2000-12-26 Allergan Sales, Inc. Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6127382A (en) 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ スクイブ カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU2001240658A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US6613917B1 (en) 2000-03-23 2003-09-02 Allergan, Inc. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
AU2001253540A1 (en) 2000-04-25 2001-11-07 Bristol-Myers Squibb Company Use of 5-thio-, sulfinyl- and sulfonylpyrazolo(3,4-b)-pyridines as cyclin dependent kinase inhibitors
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
AU2001212168A1 (en) 2000-10-20 2002-05-06 Bristol-Myers Squibb Pharma Company Acylsemicarbazides and their use as cyclin dependent kinase (CDK) inhibitors
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
GB0102687D0 (en) * 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2002074298A1 (en) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002092002A2 (en) * 2001-05-11 2002-11-21 The Burnham Institute Screening, diagnostic and therapeutic methods relating to riz
WO2002094183A2 (en) * 2001-05-18 2002-11-28 Tap Pharmaceutical Products Inc. A method for tumor treatment with fumagillol derivatives
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
WO2003061385A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
US6800655B2 (en) 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
WO2004026867A2 (en) * 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
WO2004039795A2 (en) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
US8404718B2 (en) * 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
WO2006077425A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
JP2009543770A (ja) * 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Cdk及びgskの阻害のためのピラゾール誘導体の組合せ剤
EP2049106A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations

Similar Documents

Publication Publication Date Title
JP2008528469A5 (enExample)
US20230210852A1 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
JP6532878B2 (ja) 組合せ医薬
KR20180054657A (ko) Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법
JP2009543768A5 (enExample)
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
CN101903025A (zh) 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
JP2017508787A (ja) 医薬化合物
KR20210003780A (ko) Axl 키나제 억제제 및 그의 용도
JP2025540925A (ja) 癌の治療におけるアゼノセルチブの断続的投与レジメン
EP4259145A1 (en) Alk-5 inhibitors and uses thereof
ES2682270T3 (es) Combinación farmacéutica sinérgica para el tratamiento del carcinoma de células escamosas de cabeza y cuello
JP6526789B2 (ja) 組み合わせ療法
US20240197729A1 (en) ALK-5 Inhibitors and Uses Thereof
EP1868435A2 (en) Combinations, methods and compositions for treating cancer
RU2426539C2 (ru) Способы лечения устойчивого к лекарственным средствам рака
Chu et al. Basic and clinical pharmacology
CN105050602B (zh) 作为pi3激酶抑制剂的吡啶化合物
RU2006138864A (ru) Ингибиторы митотического кинезина
JP7594009B2 (ja) 癌治療のための併用療法
RU2425677C2 (ru) Соединения, предназначенные для использования в фармацевтике
EP3452447A1 (en) Inhibitors of ires-mediated protein synthesis
TW202131925A (zh) 治療癌症之方法
TW202606693A (zh) 藥物組合產品及其用途
Evans et al. Principles of chemotherapy and drug development